Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

(2022) Reinhard Dummer et al.   JOURNAL OF CLINICAL ONCOLOGY

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma

(2022) Alessandro Nepote et al.   Journal of Clinical Medicine

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies

(2022) Julia R. Dixon-Douglas et al.   Current Oncology Reports

First‐line atezolizumab monotherapy in patients with advanced BRAF V600 wild‐type melanoma

(2021) Sergio Jobim de Azevedo et al.   Pigment Cell & Melanoma Research

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma

(2020) Reinhard Dummer et al.   JAMA Oncology

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

(2020) Pier Francesco Ferrucci et al.   Journal for ImmunoTherapy of Cancer

Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab

(2019) Omid Hamid et al.   CLINICAL CANCER RESEARCH

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

(2019) Ryan J. Sullivan et al.   NATURE MEDICINE

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

(2019) Paolo Antonio Ascierto et al.   NATURE MEDICINE

Immunological effects of BRAF+MEK inhibition

(2018) Paolo A. Ascierto et al.   OncoImmunology

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

(2018) Sunilkumar Kakadia et al.   OncoTargets and Therapy

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma

(2016) Teresa Amaral et al.   Expert Review of Anticancer Therapy

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

(2014) James Larkin et al.   LANCET ONCOLOGY

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer

(2014) J. A. Wargo et al.   Cancer Discovery

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY